Table 2.
Index | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
Age | ||||
≥ 65 years old | 0.746 (0.433–1.285) | 0.290 | ||
< 65 years old | Reference | |||
Race | ||||
White | Reference | |||
Others | 0.786 (0.109–5.662) | 0.811 | ||
Initial stage | ||||
III–IV | 0.785 (0.515–1.197) | 0.261 | ||
Others | Reference | |||
Recurrence type | ||||
Newly diagnosed | 0.664 (0.425–1.038) | 0.072 | ||
Others | Reference | |||
Disease-free interval | ||||
Newly metastatic disease | 0.625 (0.404–0.966) | 0.035 | 0.574 (0.367–0.898) | 0.015 |
Others | Reference | Reference | ||
Disease site | ||||
Visceral | 1.771 (1.129–2.778) | 0.013 | 1.847 (1.167–2.925) | 0.009 |
Nonvisceral | Reference | Reference | ||
Bone-only metastasis | 0.683 (0.385–1.211) | 0.192 | ||
Others | Reference | |||
Number of disease sites | ||||
≥ 3 | 1.609 (1.055–2.455) | 0.027 | 1.579 (1.017–2.450) | 0.042 |
1, 2 | Reference | Reference | ||
Derived neutrophil-to-lymphocyte ratioa | ||||
≥ 1.04 | 3.369 (2.134–5.320) | < 0.001 | 3.314 (2.090–5.256) | < 0.001 |
< 1.04 | Reference | Reference |
CI, confidence interval; HR, hazard ratio
aMeasured at cycle 2 day 1